Patent details

LUC00345 Product Name: atezolizumab

Basic Information

Publication number:
LUC00345
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP222159915
Legal Status:
Pending & Published
Application number:
LUC00345
First applicant's nationality:
Procedural language:
French

Paediatric Extension

SPC Extension Filing Date:
07/06/2024
SPC Extension Agent Name:
OFFICE FREYLINGER S.A.
SPC Extension Status:
Pending & Published
SPC Extension Grant Date:
SPC Extension Rejection Date:

Marketing Authorization

Marketing Authorization Number:
EU/1/17/1220
Marketing Authorization Type:
Marketing Authorization Date:
25/09/2017
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
04/06/2024
First Marketing Authorization date:
25/09/2017
Grant date:
Activation date:
Publication date:
04/06/2024
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
25/09/2032
SPC Extension Expiration:
25/03/2033
Rejection date:
Withdrawal date:

Owner

From:
04/06/2024
 
 

Name:
F. Hoffmann-La Roche AG
Address:
Grenzacherstrasse 124, 4070 Basel, Switzerland (CH)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
04/06/2024
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2024/09
Publication date:
11/07/2024
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPCX1
Bulletin edition number:
2024/09
Publication date:
11/07/2024
Description:
Section G : Applications for extensions for pediatric use – I1E publication

Annual Fees

Annual Fee Due Date:
31/12/2029
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer: